Physician profile
Brian Keith Griffith
NPI 1437199056
$8,754.94
in general payments reported to CMS, 2019-2025
18 companies · $743 in 2025
The $743 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $87.74 · 2021: $472 · 2022: $153 · 2023: $5,929 · 2024: $768 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,378 · Food and Beverage: $2,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,378.06 |
| Food and Beverage | $2,060.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $6,613.53 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Abbvie INC. | $458.59 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $316.25 | 2019-2025 | Veritas Vision System, Tecnis Iol |
| Ivantis, INC | $252.28 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $219.56 | 2020-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $134.74 | 2019-2023 | Cequa |
| Omeros Corporation | $125.65 | 2019 | |
| Allergan, INC. | $117.09 | 2019-2020 | |
| Beaver-Visitec International, INC. | $115.98 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $95.61 | 2022-2025 | Vyzulta, Infuse |
| Sight Sciences, INC. | $94.40 | 2023-2024 | Omni Surgical System |
| Harrow Eye, LLC | $51.03 | 2024-2025 | Iheezo, Vevye |
| Sumitomo Pharma America, INC. | $44.31 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $40.91 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.84 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $21.15 | 2021 | |
| Glaxosmithkline, LLC. | $16.38 | 2021 | |
| Thea Pharma INC. | $13.64 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.